Education
About Us
Working with TipRanks
Follow Us
Protara Therapeutics, Inc. (TARA)
:TARA
TARA Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.60 - $10.48
Previous CloseN/A
Volume145.20K
Average Volume (3M)389.68K
Market Cap
$118.06M
Enterprise Value$53.28M
Total Cash (Recent Filing)$124.36M
Total Debt (Recent Filing)$4.23M
Price to Earnings (P/E)―
Beta1.37
Next Earnings
Aug 11, 2025EPS Estimate
-0.37Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.29
Shares Outstanding38,581,863
10 Day Avg. Volume241,303
30 Day Avg. Volume389,679
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap0.45
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-641.93
Enterprise Value/Ebitda-1.04
Forecast
1Y Price Target
$19.50Price Target Upside517.09% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
Bulls Say, Bears Say
Bulls Say
Clinical TrialsProtara's TARA-002 has shown a similar efficacy and slightly better safety profile compared to BCG in the Phase 2 ADVANCED-2 trial in BCG-Naive NMIBC patients.
Market OpportunityWith three major catalysts in the next 12 months, an undervalued pipeline asset with a large market opportunity, as well as negative news for competitors presenting clear openings for Protara, the analyst is initiating on TARA with a BUY rating and $21 PT.
Regulatory ProgressProtara recently received alignment with the FDA on the registration trial for IV Choline in Parenteral Support patients, indicating progress in its clinical pipeline.
Bears Say
BCG Supply IssuesThere is a persistent supply shortage of BCG, which has been restricting access to patients worldwide for over 10 years.
BCG Treatment ConcernsModerate-to-high rates of bladder-related toxicity and systemic, flu-like syndrome are notable concerns with BCG treatment.
Market ValuationProtara has three diverse, late-stage clinical programs, two of which are fairly de-risked—but stock is trading at cash value.
Protara Therapeutics News
TARA FAQ
What was Protara Therapeutics, Inc.’s price range in the past 12 months?
Protara Therapeutics, Inc. lowest stock price was $1.59 and its highest was $10.48 in the past 12 months.
What is Protara Therapeutics, Inc.’s market cap?
Protara Therapeutics, Inc.’s market cap is $118.06M.
When is Protara Therapeutics, Inc.’s upcoming earnings report date?
Protara Therapeutics, Inc.’s upcoming earnings report date is Aug 11, 2025 which is in 3 days.
How were Protara Therapeutics, Inc.’s earnings last quarter?
Protara Therapeutics, Inc. released its earnings results on May 08, 2025. The company reported -$0.29 earnings per share for the quarter, beating the consensus estimate of -$0.452 by $0.162.
Is Protara Therapeutics, Inc. overvalued?
According to Wall Street analysts Protara Therapeutics, Inc.’s price is currently Undervalued.
Does Protara Therapeutics, Inc. pay dividends?
Protara Therapeutics, Inc. does not currently pay dividends.
What is Protara Therapeutics, Inc.’s EPS estimate?
Protara Therapeutics, Inc.’s EPS estimate is -0.37.
How many shares outstanding does Protara Therapeutics, Inc. have?
Protara Therapeutics, Inc. has 38,581,863 shares outstanding.
What happened to Protara Therapeutics, Inc.’s price movement after its last earnings report?
Protara Therapeutics, Inc. reported an EPS of -$0.29 in its last earnings report, beating expectations of -$0.452. Following the earnings report the stock price went up 0.597%.
Which hedge fund is a major shareholder of Protara Therapeutics, Inc.?
Currently, no hedge funds are holding shares in TARA
Protara Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$19.50 (517.09% Upside)
$19.50 (517.09% Upside)
Blogger Sentiment
Bullish
TARA Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 202.3K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $63.8K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▲ 0.6%
Last 30 Days ▼ 1.4%
Last 30 Days ▼ 1.4%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
52.17%
12-Months-Change
Fundamentals
Return on Equity
-41.88%
Trailing 12-Months
Asset Growth
147.39%
Trailing 12-Months
Company Description
Protara Therapeutics, Inc.
Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the identifying and advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy for the treatment of lymphatic malformations. It also develops intravenous choline chloride, an investigational phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease. The company was formerly known as ArTara Therapeutics, Inc. and changed its name to Protara Therapeutics, Inc. in May 2020. Protara Therapeutics, Inc. is headquartered in New York, New York.
TARA Stock 12 Month Forecast
Average Price Target
$19.50
▲(517.09% Upside)
Technical Analysis
Protalix
―
TuHURA Biosciences
―
Skye Bioscience
―
Orchestra BioMed Holdings
―
Zura Bio
―
Ownership Overview
9.26% Insiders
4.77% Mutual Funds
43.67% Other Institutional Investors
34.72% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---